Reference no: EM133049230

Describe and explain one type of patent-evergreening strategy such as a new formulationsecondary patenting (also called ) used by brand-name companies as described in the Osakwe and Rizvireading. Do strategies like this enhance or hamper innovation?

The authors of "Secondary Patenting . . ." suggest various changes to pharmaceutical or patent policy in the discussion. Discuss one of these proposed policies and its implications for pharmaceutical innovation.

List three patents on OxyContin that belong to Purdue Pharma (search USPTO or patents.google.com; watch screencast tutorial). Comment on the types of patenting strategies used by Purdue for extending patenting exclusivity for OxyContin (new indications, formulations, etc.).

Describe and explain an FDA-based market exclusivity strategy such as pediatric exclusivity used by brand-name companies as described in the Brennan article or Osakwe and Rizvi reading. How can a drug/biologic get that kind of exclusivity from the FDA?

The authors of "Strategies That Delay . . ." describe four strategies that pharmaceutical companies often use to delay market entry of generic drugs. Describe one of those strategies, then recommend policy changes to deter companies from using that strategy and the implications of those changes for the pharmaceutical industry.